Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance...
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
About this item
Full title
Author / Creator
Publisher
Dove Medical Press
Journal title
Language
English
Formats
Publication information
Publisher
Dove Medical Press
More information
Scope and Contents
Contents
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, USAAbstract: Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion on...
Alternative Titles
Full title
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_68b28e8f664340d38d1dadfbd37c753b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_68b28e8f664340d38d1dadfbd37c753b
Other Identifiers
ISSN
1177-8881
E-ISSN
1177-8881
